Reports Q4 revenue $22M, consensus $22.13M.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on NKTR:
- Nektar Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results
- Nektar price target lowered to $3 from $5 at SVB Securities
- Nektar Plunges after Topline Data Misses Primary Endpoint
- Nektar downgraded to Underperform from Hold at Jefferies
- Nektar down 31% afterhours after update on rezpegaldesleukin in lupus